Cargando…

Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis

BACKGROUND: Exportin 1 (XPO1), a nuclear export protein, participates in many biological processes, including mRNA transport, nucleocytoplasmic transport, nuclear protein export, regulation of mRNA stability, and drug response. XPO1 plays key roles in many cancer types and may serve as a potential b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lei, Luo, Baiwei, Wang, Liang, Chen, Wei, Jiang, Manyu, Zhang, Nengwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797940/ https://www.ncbi.nlm.nih.gov/pubmed/35116322 http://dx.doi.org/10.21037/tcr-21-1646

Ejemplares similares

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

Pan-cancer analysis reveals cooperativity of both strands of microRNA that regulate tumorigenesis and patient survival
por: Mitra, Ramkrishna, et al.
Publicado: (2020)

Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy
por: Tu, Zewei, et al.
Publicado: (2023)

A Pan-Cancer Analysis of the Role of Selenoprotein P mRNA in Tumorigenesis
por: Yang, Yanni, et al.
Publicado: (2021)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

A Pan-Cancer Analysis Revealing the Dual Roles of Lysine (K)-Specific Demethylase 6B in Tumorigenesis and Immunity
por: Ding, Jia-Tong, et al.
Publicado: (2022)

Regulation of XPO5 phosphorylation by PP2A in hepatocellular carcinoma
por: Li, Jiao, et al.
Publicado: (2022)

A Comprehensive and Systematic Analysis Revealed the Role of ADAR1 in Pan-Cancer Prognosis and Immune Implications
por: Zhu, Jianlin, et al.
Publicado: (2023)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

A Pan-Cancer Analysis of UBE2S in Tumorigenesis, Prognosis, Pathway, Immune Infiltration and Evasion, and Therapy Response from an Immune-Oncology Perspective
por: Bao, Haili, et al.
Publicado: (2022)

A pan-cancer analysis revealing the role of LFNG, MFNG and RFNG in tumor prognosis and microenvironment
por: Gong, Xun, et al.
Publicado: (2023)

A pan-cancer analysis reveals role of clusterin (CLU) in carcinogenesis and prognosis of human tumors
por: Fu, Yizhe, et al.
Publicado: (2023)

A Radiosensitivity Gene Signature and XPO1 Predict Clinical Outcomes for Glioma Patients
por: Wu, Shan, et al.
Publicado: (2020)

Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy
por: Zhao, Xiashuang, et al.
Publicado: (2023)

Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis
por: Ye, Yingquan, et al.
Publicado: (2022)

Evaluating the Oncogenic and Tumor Suppressor Role of XPO5 in Different Tissue Tumor Types
por: Khan, Munazza, et al.
Publicado: (2018)

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
por: Binder, Adam F., et al.
Publicado: (2023)

Role of CD68 in tumor immunity and prognosis prediction in pan-cancer
por: Zhang, Jingwei, et al.
Publicado: (2022)

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling
por: Long, Huideng, et al.
Publicado: (2023)

Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation
por: Zhao, Cheng, et al.
Publicado: (2022)

Systematic analysis reveals a pan-cancer SNHG family signature predicting prognosis and immunotherapy response
por: Zheng, Haotian, et al.
Publicado: (2023)

Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis
por: Lin, Tong, et al.
Publicado: (2021)

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
por: Deng, Manman, et al.
Publicado: (2020)

Association of microRNA biosynthesis genes XPO5 and RAN polymorphisms with cancer susceptibility: Bayesian hierarchical meta-analysis
por: Shao, Yi, et al.
Publicado: (2020)

CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma
por: Ma, Chao, et al.
Publicado: (2019)

Systematic Pan-Cancer Population-Based Analysis Reveals the Incidence and Prognosis of Lung Metastases at Diagnosis
por: Liang, Xiaohong, et al.
Publicado: (2021)

CRISPR-based screening identifies XPO7 as a positive regulator of senescence
por: Li, Lan-Zhu, et al.
Publicado: (2023)

Role of SERCA3 in the Prognosis and Immune Function in Pan-Cancer
por: Li, Jiajia, et al.
Publicado: (2022)

Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response
por: Zheng, Hong, et al.
Publicado: (2023)

Pan-precancer and cancer DNA methylation profiles revealed significant tissue specificity of interrupted biological processes in tumorigenesis
por: Zhang, Feifan, et al.
Publicado: (2023)

Integrative Pan-Cancer Analysis of KIF15 Reveals Its Diagnosis and Prognosis Value in Nasopharyngeal Carcinoma
por: Mi, Jinglin, et al.
Publicado: (2022)

A pan-cancer analysis revealed the role of the SLC16 family in cancer
por: Li, Jun, et al.
Publicado: (2021)

Targeting XPO6 inhibits prostate cancer progression and enhances the suppressive efficacy of docetaxel
por: Wang, Huming, et al.
Publicado: (2023)

XPO1-dependent nuclear export as a target for cancer therapy
por: Azizian, Nancy G., et al.
Publicado: (2020)

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
por: Walker, Janek S., et al.
Publicado: (2021)

Pan-cancer analysis reveals IGFL2 as a potential target for cancer prognosis and immunotherapy
por: Wang, Yuqi, et al.
Publicado: (2023)

A pan-cancer landscape of centromere proteins in tumorigenesis and anticancer drug sensitivity
por: Shi, Yuan-Xiang, et al.
Publicado: (2023)

Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction
por: Song, Junquan, et al.
Publicado: (2022)

Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy
por: Liu, Jinhui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_993tqf00hqg6uf35ke5fatggpm